Hepatic glycogen storage diseases are associated to microbial dysbiosis.
Adolescent
Angiotensin-Converting Enzyme Inhibitors
Case-Control Studies
Child
Cross-Sectional Studies
Dysbiosis
Energy Intake
Feces
Female
Gastrointestinal Microbiome
Glycogen Storage Disease
/ microbiology
Humans
Hydrogen-Ion Concentration
Inflammation
Inflammatory Bowel Diseases
/ microbiology
Leukocyte L1 Antigen Complex
Liver
/ metabolism
Male
Obesity
/ complications
Overweight
/ complications
Phenotype
Principal Component Analysis
RNA, Ribosomal, 16S
/ genetics
Starch
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
23
08
2018
accepted:
17
03
2019
entrez:
3
4
2019
pubmed:
3
4
2019
medline:
24
12
2019
Statut:
epublish
Résumé
The gut microbiome has been related to several features present in Glycogen Storage Diseases (GSD) patients including obesity, inflammatory bowel disease (IBD) and liver disease. The primary objective of this study was to investigate associations between GSD and the gut microbiota. Twenty-four GSD patients on treatment with uncooked cornstarch (UCCS), and 16 healthy controls had their faecal microbiota evaluated through 16S rRNA gene sequencing. Patients and controls were ≥3 years of age and not on antibiotics. Faecal pH, calprotectin, mean daily nutrient intake and current medications were recorded and correlated with gut microbiome. Patients' group presented higher intake of UCCS, higher prevalence of IBD (n = 04/24) and obesity/overweight (n = 18/24) compared to controls (n = 0 and 06/16, respectively). Both groups differed regarding diet (in patients, the calories' source was mainly the UCSS, and the intake of fat, calcium, sodium, and vitamins was lower than in controls), use of angiotensin-converting enzyme inhibitors (patients = 11, controls = 0; p-value = 0.001) multivitamins (patients = 22, controls = 01; p-value = 0.001), and mean faecal pH (patients = 6.23; controls = 7.41; p = 0.001). The GSD microbiome was characterized by low diversity and distinct microbial structure. The operational taxonomic unit (OTU) abundance was significantly influenced by faecal pH (r = 0.77; p = 6.8e-09), total carbohydrate (r = -0.6; p = 4.8e-05) and sugar (r = 0.057; p = 0.00013) intakes. GSD patients presented intestinal dysbiosis, showing low faecal microbial diversity in comparison with healthy controls. Those findings might be due to the disease per se, and/or to the different diets, use of UCSS and of medicines, and obesity rate found in patients. Although the main driver of these differences is unknown, this study might help to understand how the nutritional management affects GSD patients.
Identifiants
pubmed: 30939160
doi: 10.1371/journal.pone.0214582
pii: PONE-D-18-24856
pmc: PMC6445422
doi:
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Leukocyte L1 Antigen Complex
0
RNA, Ribosomal, 16S
0
Starch
9005-25-8
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0214582Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
Sci Rep. 2018 Jan 23;8(1):1466
pubmed: 29362454
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
ISME J. 2012 Aug;6(8):1621-4
pubmed: 22402401
PLoS One. 2015 Aug 05;10(8):e0134893
pubmed: 26244577
Inflamm Bowel Dis. 2016 May;22(5):1137-50
pubmed: 27070911
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
Nat Methods. 2013 Dec;10(12):1200-2
pubmed: 24076764
Eur J Pediatr. 2002 Oct;161 Suppl 1:S2-9
pubmed: 12373565
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Nat Rev Endocrinol. 2010 Dec;6(12):676-88
pubmed: 20975743
Eur J Pediatr. 2002 Oct;161 Suppl 1:S120-3
pubmed: 12373585
J Nutr. 1992 Jan;122(1):178-90
pubmed: 1370325
Trends Biotechnol. 2015 Sep;33(9):496-503
pubmed: 26210164
J Microbiol Methods. 2011 Jul;86(1):42-51
pubmed: 21457733
Int J Mol Sci. 2015 Apr 02;16(4):7493-519
pubmed: 25849657
Gut. 2017 May;66(5):813-822
pubmed: 28179361
Gastroenterology. 2012 Oct;143(4):913-6.e7
pubmed: 22728514
Orphanet J Rare Dis. 2015 Jul 29;10:91
pubmed: 26219379
Endocrinol Diabetes Metab Case Rep. 2013;2013:130056
pubmed: 24683476
Gastroenterol Hepatol (N Y). 2017 Jan;13(1):53-56
pubmed: 28420947
Microb Ecol. 2016 Aug;72(2):443-7
pubmed: 27220974
Med Hypotheses. 2010 Feb;74(2):214-5
pubmed: 19836146
JIMD Rep. 2015;24:123-8
pubmed: 26093626
Genet Med. 2014 Nov;16(11):e1
pubmed: 25356975
Folia Microbiol (Praha). 2012 Sep;57(5):409-13
pubmed: 22562492
Eur J Pediatr. 2002 Oct;161 Suppl 1:S112-9
pubmed: 12373584
Gut Microbes. 2016 May 3;7(3):189-200
pubmed: 26963409
PeerJ. 2018 Jun 13;6:e4991
pubmed: 29915701
J Inherit Metab Dis. 2016 Sep;39(5):697-704
pubmed: 27106217
Nat Rev Genet. 2017 Nov;18(11):690-699
pubmed: 28824167
Genet Med. 2010 Jul;12(7):446-63
pubmed: 20631546
Gut. 2016 Feb;65(2):330-9
pubmed: 26338727
Eur J Pediatr. 2002 Oct;161 Suppl 1:S35-9
pubmed: 12373568
J Inherit Metab Dis. 2015 May;38(3):537-43
pubmed: 25633903
J Microbiol Methods. 2014 Dec;107:30-7
pubmed: 25193439
Hepatology. 2011 Aug;54(2):562-72
pubmed: 21574172
JAMA. 2013 Apr 10;309(14):1447-9
pubmed: 23571560
Eur J Pediatr. 2002 Oct;161 Suppl 1:S20-34
pubmed: 12373567
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
J Immunol. 2016 Mar 1;196(5):2300-2308
pubmed: 26810228
Microb Ecol Health Dis. 2015 Feb 02;26:26191
pubmed: 25651997
Probiotics Antimicrob Proteins. 2019 Mar;11(1):143-149
pubmed: 29441457
World J Gastroenterol. 2007 May 14;13(18):2541-53
pubmed: 17552001
J Gastroenterol. 2018 Mar;53(3):305-353
pubmed: 29429045
Nucleic Acids Res. 2017 Jul 3;45(W1):W180-W188
pubmed: 28449106